News & Views | Published:

CANCER

Therapy resistance beyond cellular dormancy

It is commonly accepted that disseminated tumour cells survive cytotoxic chemotherapy because they are not proliferating. A new study now finds that, in contrast to this long-standing concept, both dormant and proliferative cancer cells can be protected from chemotherapy when they reside at the perivascular niche.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Shapiro, C. L. & Recht, A. New Engl. J. Med. 344, 1997–2008 (2001).

  2. 2.

    Early Breast Cancer Trialists’ Collaborative, G. Lancet Oncol. 19, 27–39 (2018).

  3. 3.

    Pantel, K. et al. J. Natl Cancer Inst. 85, 1419–1424 (1993).

  4. 4.

    Braun, S. et al. J. Clin. Oncol. 18, 80–86 (2000).

  5. 5.

    Carlson, P. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-018-0267-0 (2019).

  6. 6.

    Werner-Klein, M. et al. Nat. Commun. 9, 595 (2018).

  7. 7.

    Hosseini, H. et al. Nature 540, 552–558 (2016).

  8. 8.

    Spencer, J. A. et al. Nature 508, 269–273 (2014).

  9. 9.

    Fluegen, G. et al. Nat. Cell Biol. 19, 120–132 (2017).

  10. 10.

    Sosa, M. S. et al. Nat. Commun. 6, 6170 (2015).

  11. 11.

    Joyce, J. A. & Pollard, J. W. Nat. Rev. Cancer 9, 239–252 (2009).

  12. 12.

    Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Nat. Rev. Cancer 13, 714–726 (2013).

  13. 13.

    Minchinton, A. I. & Tannock, I. F. Nat. Rev. Cancer 6, 583–592 (2006).

  14. 14.

    Croucher, P. I., McDonald, M. M. & Martin, T. J. Nat. Rev. Cancer 16, 373–386 (2016).

  15. 15.

    Chuang, H. N. et al. Glia 61, 1331–1346 (2013).

Download references

Author information

Competing interests

The authors declare no competing interests.

Correspondence to Christoph A. Klein.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1: Mechanisms of therapy resistance in manifest metastasis versus early systemic cancer.